ライフサイエンスコーパス: allogeneic transplant

1 tion in complications were substantial after allogeneic transplant.

2 ng lavages of mice given either syngeneic or allogeneic transplant.

3 ogical mechanisms in the presence of a fully allogeneic transplant.

4 uding donor lymphocyte infusions or a second allogeneic transplant.

5 3 g/m(2) twice daily on days 1, 3, 5) and/or allogeneic transplant.

6 mission is the prerequisite for a successful allogeneic transplant.

7 nsplantation, followed by a nonmyeloablative allogeneic transplant.

8 cell immune response to an H-Y antigen after allogeneic transplant.

9 otoxic T lymphocytes and function to destroy allogeneic transplants.

10 are upregulated in rejected versus accepted allogeneic transplants.

11 t or relapsing disease after T-cell-depleted allogeneic transplants.

12 n used as stem cells for both autologous and allogeneic transplants.

13 ls are necessary for initiating rejection of allogeneic transplants.

14 their role in acute and chronic rejection of allogeneic transplants.

15 portant component of pathogenic responses to allogeneic transplants.

16 stitution of hematopoiesis in autologous and allogeneic transplants.

17 elopment of typical microvascular lesions in allogeneic transplants.

18 ients who would not qualify for conventional allogeneic transplants.

19 ative to bone marrow for patients undergoing allogeneic transplants.

20 , n=3, P<0.01) compared with vehicle-treated allogeneic transplants.

21 in the lymphoid tissue, such as viruses and allogeneic transplants.

22 all were previously treated and two received allogeneic transplants.

23 Mortality was significantly higher in allogeneic transplants (55.1%, p < 0.001) and in those w

24 oma patients who underwent reduced-intensity allogeneic transplants, 66.3% had responses, most of whi

25 We studied 19,229 patients who received allogeneic transplants (97.2 percent) or syngeneic trans

26 Four/10 patients with prior allogeneic transplant achieved at least PR.

27 nhibitory receptor ILT2 and its ligands, and allogeneic transplant-activated MDSCs were obtained in m

28 Allogeneic transplant and higher APACHE III scores, but

29 uced T cells can control the rejection of an allogeneic transplant and suggests that T-cell Foxp3 gen

30 eared the P. carinii but only the mice given allogeneic transplants and anti-IFNgamma had increased l

31 Following reciprocal MHC-disparate allogeneic transplants and during de novo NK-cell recove

32 patterns, including induction intensity and allogeneic transplant, and treatment complications, as a

33 death rate, complete remission rate, use of allogeneic transplants, and overall survival in AML (non

34 sease is the major risk of reduced-intensity allogeneic transplants, and treatment methods need refin

35 es were 66% in TBI+day 4 vs. 0% in TBI+day 0 allogeneic transplanted animals by day +60 (P<0.001).

36 raftment between the TBI+day 0 and TBI+day 4 allogeneic transplanted animals.

37 In the older CLL patients, nonmyeloablative allogeneic transplants are better tolerated than myeloab

38 Nonmyeloablative allogeneic transplants are less effective in heavily dis

39 Reduced-intensity allogeneic transplants are promising, increasingly used

40 among 1418 patients who received their first allogeneic transplants at our center in Seattle in the p

41 d a unique profile was detected in rejecting allogeneic transplants (BALB/c --> C57BL/6) as compared

42 In allogeneic transplants, both donor and recipient CD73 we

43 tients with myeloid malignancies who need an allogeneic transplant, but lack a suitable sibling donor

44 Therefore, complete tolerance to an allogeneic transplant can only be achieved if all cellul

45 ell as rejection and regulatory tolerance of allogeneic transplants, can occur in recipient mice lack

46 In some of the allogeneic transplants, CD8+ lymphocytes were depleted b

47 t who has failed imatinib but has a possible allogeneic transplant donor, should one offer dasatinib

48 patients aged 0 to 39 years, utilization of allogeneic transplant for acute lymphoblastic leukemia w

49 ab vedotin has been evaluated as a bridge to allogeneic transplant for patients refractory to convent

50 d with MPA 40 mg/kg per 24 hr, and untreated allogeneic transplants for 6 months (n=14 in each group)

51 arrow transplants provide the alternative to allogeneic transplants for patients lacking an HLA-match

52 t-AML (n = 545) or t-MDS (n = 323) receiving allogeneic transplants from 1990 to 2004.

53 g syngeneic transplants (group 1), untreated allogeneic transplants (group 2), allogeneic transplants

54 Recipients of allogeneic transplants had a higher probability of devel

55 Overall, reduced-intensity allogeneic transplants have been well tolerated and have

56 ects have been thought to mostly result from allogeneic transplants; however, there is a growing body

57 PM1-mutated acute myeloid leukemia (AML) for allogeneic transplant in first complete remission (CR1-a

58 y identifies those patients who benefit from allogeneic transplant in first remission.

59 t-versus-host disease (GVHD) prophylaxis for allogeneic transplant in patients conditioned with a fra

60 ly 40 published reports of reduced-intensity allogeneic transplants in lymphomas.

61 linical studies, the pertinent use of kidney allogeneic transplants in mice comes down to the judicio

62 among 1148 patients who received their first allogeneic transplants in the period from 2003 through 2

63 define better the role of reduced-intensity allogeneic transplants in treating lymphomas.

64 erred source of stem cells for many types of allogeneic transplant, in which matched related donors a

65 nt-related morbidity and mortality following allogeneic transplant, including management of acute and

66 Granzyme B and FasL were expressed in all allogeneic transplants, including those depleted of CD8+

67 Dose-reduced allogeneic transplant is a therapeutic alternative for p

68 ation of hematopoietic stem cells (HSCs) for allogeneic transplants is common in the clinical setting

69 immune response leading to the rejection of allogeneic transplants is initiated and orchestrated by

70 at allow prolonged survival of syngeneic and allogeneic transplanted islets in diabetic BALB/c and NO

71 Reduced renal binding of 99mTc-FGF-1 in the allogeneic transplanted kidney was consistent with decre

72 idual disease (MRD)(-) status, consolidative allogeneic transplant leads to acceptable long-term dise

73 Allogeneic transplant led to donor-recipient chimerism i

74 Because an allogeneic transplanted liver may induce tolerance to it

75 Notably, PBC recurs in an allogeneic transplanted liver, suggesting generic rather

76 lymphocytic leukemia (CLL) who relapse after allogeneic transplant may achieve durable remission foll

77 ells, which are generally thought to protect allogeneic transplants, may actually be potent facilitat

78 d PBSC maintain their GVL effect in a murine allogeneic transplant model (B6 --> B6D2F1).

79 Gy total body irradiation-based regimens and allogeneic transplants (MUD, n = 38; UCB, n = 15; mismat

80 Allogeneic transplant of purified hematopoietic stem cel

81 After autologous or allogeneic transplants of peripheral blood stem cells (P

82 Thirty-seven patients received allogeneic transplants, of which 18 were T-cell-depleted

83 gene correction either by matched littermate allogeneic transplant or autologous gene therapy were ev

84 relevant to cancer patients with preexisting allogeneic transplants or autoimmune disease who are und

85 to their potential to support autologous and allogeneic transplant paradigms.

86 Thirty-two allogeneic transplant patients and their donors were imm

87 ound in post-DLI responders and not in other allogeneic transplant patients or healthy donors.

88 with donor genotype have been identified in allogeneic transplant patients; however, the donor contr

89 .F5 alone given IV or s.c. (groups 3 and 4), allogeneic transplants plus donor splenocyte preconditio

90 untreated allogeneic transplants (group 2), allogeneic transplants plus multiple doses of AH.F5 alon

91 significant morbidity and mortality of such allogeneic transplants precludes widespread adoption of

92 al study showed that rituximab therapy after allogeneic transplant prevented proteinuria possibly ass

93 and Marrow Transplantation, one-third of the allogeneic transplant procedures for MDS were performed

94 y was 28% in autologous compared with 70% in allogeneic transplant recipients (p = 0.0040).

95 eptor (KIR) gene expression in NK cells from allogeneic transplant recipients and their donors.

96 t-related distress was slower to recover for allogeneic transplant recipients and those with less soc

97 rogate for NETs in 103 consecutive pediatric allogeneic transplant recipients at day 0, +14, +30, +60

98 nd regulatory markers heralding early ACR in allogeneic transplant recipients but not in syngeneic tr

99 We confirmed that allogeneic transplant recipients had an impaired reconst

100 Circulating T cell sEVs enriched from allogeneic transplant recipients mediated targeted cytot

101 the prevaccine and postvaccine titers of 292 allogeneic transplant recipients who were immunized with

102 udied a multi-institutional cohort of 28 874 allogeneic transplant recipients with 189 solid malignan

103 Allogeneic transplant recipients with graft-versus-host

104 We conclude that allogeneic transplant recipients with GVHD have (1) incr

105 ompared with infected control mice, infected allogeneic transplant recipients with GVHD showed increa

106 However, infected allogeneic transplant recipients with GVHD showed lower

107 Anti-TGF-beta treatment of allogeneic transplant recipients with GVHD significantly

108 alveolar lavage (BAL) fluid of mock-infected allogeneic transplant recipients with GVHD, which increa

109 the increased severity of HSV-1 pneumonia in allogeneic transplant recipients with GVHD.

110 2 transgenic) were used as T cell donors for allogeneic transplant recipients, and graft-vs-host dise

111 tion of life-threatening viral infections in allogeneic transplant recipients, demonstrated safety an

112 tion of Clr-b(-/-) BM cells also occurred in allogeneic transplant recipients, where it was reversed

113 onor (n = 177) and unrelated-donor (n = 106) allogeneic transplant recipients.

114 in part, the functional immunodeficiency in allogeneic transplant recipients.

115 s can reduce the incidence of CMV disease in allogeneic transplant recipients.

116 on of tumor immunity and the amelioration of allogeneic transplant rejection.

117 onic graft-versus-host disease (cGVHD) after allogeneic transplant remains a significant cause of mor

118 Mice that received allogeneic transplant showed an increase in nuclear 5-LO

119 currently ranges from vaccine development to allogeneic transplant strategies designed to induce a gr

120 d behavior recovery regardless autologous or allogeneic transplant, suggesting a predictive power of

121 These data indicate that allogeneic transplant survivors, particularly those irra

122 Skin samples from tolerant long-term allogeneic transplanted, syngeneic transplanted, rejecte

123 r timing of intubation, or the percentage of allogeneic transplants that were not HLA-identical.

124 major histocompatibility barriers show that allogeneic transplanted thymi are not rejected, and allo

125 on is limited because of immune rejection of allogeneic transplanted tissue and potential adverse sid

126 effector T cells and Tregs serve to prevent allogeneic transplant tolerance.

127 n and fibrogenesis in syngeneic transplants, allogeneic transplants treated with MPA 40 mg/kg per 24

128 From 2017 to 2018, adult (40-84 years) allogeneic transplant utilization for acute myeloid leuk

129 In this cohort study of autologous and allogeneic transplant utilization for hematologic cancer

130 An allogeneic transplant was carried out in first CHR mainl

131 Forty-one consecutive allogeneic transplants were performed on patients with a

132 MCMV D+/R- and D-/R- allogeneic transplants were performed with cyclosporine

133 Six syngeneic and 25 allogeneic transplants were performed.

134 The role of allogeneic transplant with nonmyeloablative conditioning

135 allow the induction of specific tolerance to allogeneic transplants without affecting other immune fu